CN102008475A - Application of quinolizidine in preparing tumor treatment drugs - Google Patents
Application of quinolizidine in preparing tumor treatment drugs Download PDFInfo
- Publication number
- CN102008475A CN102008475A CN2010102791076A CN201010279107A CN102008475A CN 102008475 A CN102008475 A CN 102008475A CN 2010102791076 A CN2010102791076 A CN 2010102791076A CN 201010279107 A CN201010279107 A CN 201010279107A CN 102008475 A CN102008475 A CN 102008475A
- Authority
- CN
- China
- Prior art keywords
- cell
- eulexine
- tumor
- aloperine
- sparteine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to application of quinolizidine extracted from Sophora plants in preparing tumor treatment drugs. The quinolizidine can be used for treating tumors including leukemia, lymphoma, cancer of the liver, cancer of the esophagus and lung cancer. A combined medical auxiliary material including therapy effective dose of active components: aloperine, retaminesparteine and laburnine is utilized to prepare clinically applied dosage forms like injections, tablets, capsules, release-controlled pills and the like.
Description
Technical field
The invention belongs to pharmaceutical field, be specifically related to of the application of quinolizidine alkaloid at the medicine for treating tumor thing.
Technical background
Oncotherapy mainly contains operation, radiation and chemotherapy at present, because leukemia remains the medicine chemotherapy at clinical first-selected therapeutic scheme.Therefore from plant research and development high-efficiency low-toxicity natural anti-cancer drugs or lead compound important practical sense is arranged.Experimental example of the present invention has also been selected the tumor cell of China's digestive tract occurred frequently and respiratory tract cancer for use except that having selected the leukaemia for use.
The selected tumor cell of the present invention is all taken from clinical tumor patient's cell, take from 53 years old women leukaemic as the K562 cell, the HL60 cell is taken from 36 years old women's acute promyelocytic leukemia patient, the U937 cell is taken from 37 years old male's diffusivity histocytic lymphoma, the HepG2 cell derives from 15 years old patient's liver cancer tissue, EC109 takes from 65 years old male esophageal cancer patient, and the A549 cell is taken from 58 years old male lung cancer patient.
Sophora plant belongs to the pulse family Papillionoideae, and kinds more than 90 such as shrub, arbor, rare draft are arranged, and mainly is distributed in temperate zone and subtropical zone.China all produces in north and south distributed more widely, and kind more than 30 is arranged approximately, is usually used in Chinese medicine and mainly contains Radix Sophorae Flavescentis, Herba Sophorae alopecuroidis and Radix Sophorae Tonkinensis etc.Sophora plant Chinese medicine has effects such as sterilization, antiviral, arrhythmia and antitumor.Chinese medicine is in existing over thousands of year clinical practice history of China, and its contained a large amount of active ingredient has wide research and development prospect.
Quinolizidine alkaloid from sophora plant extracts also has effects such as sterilization, antiviral, arrhythmia.The quinolizidine alkaloid can be divided into matrine type, aloperine type, sparteine type and eulexine type etc.Report that at present having the antineoplastic alkaloid from sophora plant Chinese medicine Radix Sophorae Flavescentis, Herba Sophorae alopecuroidis and Radix Sophorae Tonkinensis extraction is matrine type, as matrine, sophoridine, sophocarpine.No. 93100881.6 patents of China " purposes of sophoridine " disclose the sophoridine anticancer usage, and No. 200510064670.0 patents " Oxysophoridine is in the purposes of preparation anticarcinogen " disclose the anticancer usage of Oxysophoridine.
Aloperine type, sparteine type and eulexine type alkaloid do not appear in the newspapers as yet in the purposes of anti-tumor aspect.The aloperine type is meant aloperine, allylaloperine, N-methyl aloperine, 11-dehydrogenation aloperine; The sparteine type is meant sparteine, 13-hydroxysparteine, 17-oxo supanine, supanine, Anagyrine, Ba Puye alkali, 5,6-dehydrogenation supanine, 11,12-dehydrogenation sparteine; The eulexine type is meant eulexine, 11-pi-allyl eulexine, 12-hydroxyl eulexine, N-(2-ethoxy) eulexine, N-acetyl group eulexine, N-ethyl eulexine, N-aldehyde radical eulexine, N-Methylcytisine, 11-oxo eulexine.
Summary of the invention
The purpose of this invention is to provide a kind of quinolizidine alkaloid and be used for the treatment of the purposes of tumour medicine, specifically be meant aloperine, sparteine and eulexine in preparation.
The technical scheme that relates to of the present invention is: the quinolizidine alkaloid is used for the treatment of the application of leukemia, lymphoma, hepatocarcinoma, the esophageal carcinoma, pulmonary carcinoma tumour medicine in preparation.
Quinolizidine alkaloid of the present invention is aloperine, sparteine or the eulexine that sophora plant extracts.
Leukemia of the present invention is meant the leukemia that K562 cell, HL-60 cell cause; Lymphoma causes tumor for the U937 cell; The tumor that hepatocarcinoma causes for the HepG2 cell; The tumor that the esophageal carcinoma causes for the EC109 cell; The tumor that pulmonary carcinoma causes for the A549 cell.
The medicine that the present invention is used for the treatment of tumor is meant active ingredient aloperine, sparteine or the eulexine that uses the treatment effective dose, combination pharmaceutic adjuvant, dosage forms such as the injection of preparation clinical practice, tablet, capsule, controlled release pill.
The aloperine type is meant aloperine, allylaloperine, N-methyl aloperine, 11-dehydrogenation aloperine among the present invention; The sparteine type is meant sparteine, 13-hydroxysparteine, 17-oxo supanine, supanine, Anagyrine, Ba Puye alkali, 5,6-dehydrogenation supanine, 11,12-dehydrogenation sparteine; The eulexine type is meant eulexine, 11-pi-allyl eulexine, 12-hydroxyl eulexine, N-(2-ethoxy) eulexine, N-acetyl group eulexine, N-ethyl eulexine, N-aldehyde radical eulexine, N-Methylcytisine, 11-oxo eulexine.
The inventor is contrast with the medicine sophoridine that is used for oncotherapy, utilize hematological system tumor leukemia, lymphoma, digestive system tumor hepatocarcinoma, the esophageal carcinoma and respiratory system tumor pulmonary carcinoma kinds of tumor cells, observation has been compared aloperine, sparteine and eulexine and has been suppressed the tumor cell effect, found that aloperine, sparteine suppress above-mentioned tumor cell effect and obviously be better than sophoridine, eulexine is better than sophoridine to the inhibition effect of above-mentioned hepatocarcinoma and lung carcinoma cell.
Further experiment is discovered and is found that aloperine, sparteine and eulexine antitumor cell effect mainly suppress, induce autophagy and apoptosis to reach the antitumor cell purpose by propagation.
The present invention is that active ingredient and pharmaceutic adjuvant combination are made dosage forms such as injection, tablet, capsule for clinical practice with aloperine, sparteine and eulexine respectively.
With radix sophorae, Radix Sophorae Tonkinensis or Herba Sophorae alopecuroidis grind up, with 0.4% hydrochloric acid soaking at room temperature 7 days, totally 4 times, sucking filtration reclaims and obtains total extractum, obtain aloperine, sparteine and eulexine isoreactivity alkaloid component through technologies such as defat, acidify, alkalization and chloroform extractions again, after purity analysis is identified, be used for subsequent preparation.
Get aloperine 10 gram and add 500 milliliters of stirring and dissolving of injection water, add gradually and calculate consumption hydrochloric acid solution (concentration is 1M), add injection water to 1 liter again.Stirring, filtration, packing, sterilization, the preparation injection.Get sparteine 10 gram and add 500 milliliters of stirring and dissolving of injection water, add gradually and calculate consumption sulfuric acid solution (concentration is 1M), add injection water to 1 liter again.Stirring, filtration, packing, sterilization, the preparation injection.Get eulexine 10 gram and add 500 milliliters of stirring and dissolving of injection water, add gradually and calculate consumption hydrochloric acid solution (concentration is 1M), add injection water to 1 liter again.Stirring, filtration, packing, sterilization, the preparation injection.
Get 20 milligrams of aloperines, add medicinal adjuvant and mix, be pressed into tablet, every contains 20 milligrams of aloperines.Get 20 milligrams of sparteine, add medicinal adjuvant and mix, be pressed into tablet, every contains 20 milligrams of sparteine.Get 20 milligrams of eulexine, add medicinal adjuvant and mix, be pressed into tablet, every contains 20 milligrams of eulexine.
Get 20 milligrams of aloperines, add medicinal adjuvant and mix, incapsulate, every capsule contains 20 milligrams of aloperines.Get 20 milligrams of sparteine, add medicinal adjuvant and mix, incapsulate, every capsule contains 20 milligrams of sparteine.Get 20 milligrams of eulexine, add medicinal adjuvant and mix, incapsulate, every capsule contains 20 milligrams of eulexine.
The pharmaceutical preparation of getting above-mentioned aloperine, sparteine and the preparation of eulexine active component is diluted to experimental concentration and carries out following embodiment, and aloperine, sparteine and eulexine antitumor cell effect and purposes are described:
Embodiment 1, adopts conventional mtt assay to carry out the tumor suppression experiment, and method and result are as follows:
The MTT colorimetry is a kind of method that detects cell survival and growth.This method has been widely used in large-scale screening anti-tumor medicine, and its feature is highly sensitive, economical.
Above-mentioned each tumor cell 0.5-2 * 105 are diluted to experimental concentration with the preparation of aloperine, sparteine and eulexine preparation in 96 orifice plates, add each tumor cell respectively and handled 48 hours.Each experimental group is provided with 3 repeating holes, and negative blank hole is not for adding medicine, and the positive drug control wells is a sophoridine.The 5mg/ml MTT solution of-20 ℃ of preservations adds 10 μ l MTT solution mixings in the dissolving of room temperature lucifuge in the every hole of 96 orifice plates, placed 4 hours in cell culture incubator.In 96 orifice bores, add the three joint-trial agent of 100 μ l, continue at the cell culture incubator placement and spend the night by SDS, isopropyl alcohol and hydrochloric acid preparation.Microplate reader 570nm detects each hole OD value, calculates suppression ratio (suppression ratio=1-dosing group OD value/matched group OD value), obtains suppression ratio and be 50% drug level, i.e. IC50.IC50 represents the inhibition effect of medicine to tumor cell.
Following table is according to the OD value that records, deduct the average of reagent matched group after, the inhibition effect of calculating medicine on cell proliferation.
* IC50 represents that tumor cell is suppressed 50% used drug dose, represents with mM.The bright inhibition tumor effect of novel is good more more for drug dose.
Experimental result shows that aloperine antitumor cell effect obviously is better than sophoridine, sparteine obviously is better than sophoridine to the effect of leukemia, hepatocarcinoma, the esophageal carcinoma and lung carcinoma cell, near sophoridine, eulexine is better than sophoridine to the inhibition effect of hepatocarcinoma and lung carcinoma cell to the action effect of lymphoma cell.Experimental result is suppression ratio and drug level and the dependence that is proportionate action time of tumor cells showed also.
Embodiment 2, the inducing tumor cell autophagy:
Show that in embodiment 1 aloperine, sparteine and eulexine can suppress tumor cell proliferation, present embodiment is further verified aloperine, sparteine and eulexine antineoplastic activity.
Get among the embodiment 1 each experimental group pharmaceutical preparation effect tumor cell after 18 hours, get the 0.5ml cell and add in the 1.5ml EP pipe, add acridine orange 5 μ l, 37 ℃, 15min.Add PBS 0.5ml and abandon supernatant in 1500rpm4 ℃ of centrifugal 5min, collecting cell adds PBS 1ml again and washes twice.100 μ l PBS re-suspended cells, observation of cell on the fluorescence inverted microscope, autophagy takes place in the nucleus red coloration of discovery drug study group.Illustrate that thus pharmaceutical preparation of the present invention can suppress tumor cell proliferation by inducing above-mentioned tumor cell autophagy, reaches the expection of treatment tumor.
Embodiment 3, inducing apoptosis of tumour cell:
PARP shears and scalariform DNA agarose gel electrophoresis, and they are apoptotic important indicator and feature.The above-mentioned tumor cell of each experimental group pharmaceutical preparation continuation effect is after 48 hours in embodiment 2, the conventional immunoblotting of utilization has detected PARP and has sheared and scalariform DNA agarose gel electrophoresis, find that the above-mentioned tumor cell of pharmaceutical preparation continuation effect is after 48 hours, PARP having occurred shears and scalariform DNA, presentation of results pharmaceutical preparation of the present invention finally can be induced above-mentioned apoptosis of tumor cells, reaches the effect of treatment treatment tumor cell.
In the soluble concentration range of aloperine, sparteine and eulexine, the isolating normal person's peripheral blood lymphocytes of effect lymphocyte separation medium, or Mus source normal immortalization 3T3 cell, its activity IC50 is greater than more than tumor cell 5-10 times, illustrate that aloperine, sparteine and eulexine are less to normal cytotoxic effect, better to the tumor cell effect.
Mention aloperine toxicity less than matrine, sophocarpine in " the pharmaceutical research progress of Herba Sophorae alopecuroidis Alkaloid, yellow elegant prunus mume (sieb.) sieb.et zucc. Li Bo Chinese Pharmaceutical Affairs was rolled up 175 pages of the 3rd phases in 2002 the 16th "." research of new drug aloperine mutagenicity, woods flies, and high abundant water canceration, distortion, sudden change were rolled up 120 pages of the 2nd phases in 1991 the 3rd and are reported that also aloperine does not exist genetoxic and potential carcinogenecity under the experiment condition of report.Inventor's experimental result is consistent with general pharmacology and toxicological experiment report, illustrates that aloperine, sparteine and eulexine are safety and low toxicity, and antitumous effect is better than sophoridine, valuable anti-cancer agent.
Claims (4)
1. the quinolizidine alkaloid is in the application of preparation treatment leukemia, lymphoma, hepatocarcinoma, the esophageal carcinoma, pulmonary carcinoma tumour medicine.
2. application according to claim 1, wherein said quinolizidine alkaloid are aloperine, sparteine or the eulexine that sophora plant extracts.
3. application according to claim 2 is characterized in that described leukemia is meant the leukemia that K562 cell, HL-60 cell cause; Lymphoma causes tumor for the U937 cell; The tumor that hepatocarcinoma causes for the HepG2 cell; The tumor that the esophageal carcinoma causes for the EC109 cell; The tumor that pulmonary carcinoma causes for the A549 cell.
4. application according to claim 3, the medicine that wherein is used for the treatment of tumor is meant active ingredient aloperine, sparteine or the eulexine that uses the treatment effective dose, the combination pharmaceutic adjuvant, dosage forms such as the injection of preparation clinical practice, tablet, capsule, controlled release pill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010279107 CN102008475B (en) | 2010-09-09 | 2010-09-09 | Application of quinolizidine in preparing tumor treatment drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010279107 CN102008475B (en) | 2010-09-09 | 2010-09-09 | Application of quinolizidine in preparing tumor treatment drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102008475A true CN102008475A (en) | 2011-04-13 |
| CN102008475B CN102008475B (en) | 2012-12-19 |
Family
ID=43838946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010279107 Expired - Fee Related CN102008475B (en) | 2010-09-09 | 2010-09-09 | Application of quinolizidine in preparing tumor treatment drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102008475B (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102218065A (en) * | 2011-04-02 | 2011-10-19 | 广州汉方现代中药研究开发有限公司 | New application of aloperin in pharmacy |
| CN106822129A (en) * | 2017-03-08 | 2017-06-13 | 中国医学科学院医药生物技术研究所 | Application of the aloperine derivative in the medicine for preparing treatment tumour |
| CN106880841A (en) * | 2017-03-06 | 2017-06-23 | 中南大学湘雅医院 | Application of aloperine in preparing lung cancer radiotherapy sensitizer |
| CN108840871A (en) * | 2018-07-18 | 2018-11-20 | 陕西科技大学 | 13- hydroxyl sparteine cinnamate derivative compound with anti-tumor activity and preparation method thereof |
| CN109055313A (en) * | 2018-08-29 | 2018-12-21 | 青海七彩花生物科技有限公司 | A kind of application of alkaloid in enhancing CIK cell proliferative capacity and in terms of killing tumor activity |
| CN109045031A (en) * | 2018-09-13 | 2018-12-21 | 淮安亿泰生物科技有限公司 | A kind of alkaloid reversing lung cancer cisplatin-resistant |
| CN109172571A (en) * | 2018-09-13 | 2019-01-11 | 淮安亿泰生物科技有限公司 | A kind of alkaloid is used to reverse the purposes of lung cancer cisplatin-resistant |
| CN109172569A (en) * | 2018-09-13 | 2019-01-11 | 淮安亿泰生物科技有限公司 | A kind of alkaloid compound for preventing and treating patients with lung cancer cisplatin-resistant |
| CN109172570A (en) * | 2018-09-13 | 2019-01-11 | 淮安亿泰生物科技有限公司 | A kind of application of alkaloid in the drug of preparation prevention and treatment patients with lung cancer cisplatin-resistant |
| CN109200050A (en) * | 2018-09-13 | 2019-01-15 | 淮安亿泰生物科技有限公司 | Application of the alkaloid in terms of reversing lung cancer cisplatin-resistant |
| CN114573585A (en) * | 2020-12-01 | 2022-06-03 | 中国医学科学院药物研究所 | Alkaloid extracted from herba Sophorae Alopecuroidis, its pharmaceutical composition, and its application in preventing and treating tumor |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1231890A (en) * | 1999-02-10 | 1999-10-20 | 江西中医学院 | Anticancer drug contg. diquinolizidine structure alkaloid and preparing method thereof |
-
2010
- 2010-09-09 CN CN 201010279107 patent/CN102008475B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1231890A (en) * | 1999-02-10 | 1999-10-20 | 江西中医学院 | Anticancer drug contg. diquinolizidine structure alkaloid and preparing method thereof |
Non-Patent Citations (4)
| Title |
|---|
| 《中国医院药学杂志》 20091231 靳毅等 氧化苦参碱诱导人食管癌细胞株Eca109 凋亡的实验观察 第891－894页 1－4 第29卷, 第11期 2 * |
| 《农垦医学》 20100831 高红英等 苦豆子种子中生物碱的研究进展 第340－343页 1－4 第32卷, 第4期 2 * |
| 《特产研究》 20041231 胡淑平等 苦参类生物碱抗肿瘤作用 第43－46页 1－4 , 第3期 2 * |
| 浩云: "蔬菜为什么能防癌", 《广西质量监督导报》 * |
Cited By (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102218065A (en) * | 2011-04-02 | 2011-10-19 | 广州汉方现代中药研究开发有限公司 | New application of aloperin in pharmacy |
| CN102218065B (en) * | 2011-04-02 | 2014-06-11 | 广州白云山汉方现代药业有限公司 | New application of aloperin in pharmacy |
| CN106880841A (en) * | 2017-03-06 | 2017-06-23 | 中南大学湘雅医院 | Application of aloperine in preparing lung cancer radiotherapy sensitizer |
| CN106880841B (en) * | 2017-03-06 | 2018-01-16 | 中南大学湘雅医院 | Application of aloperine in preparing lung cancer radiotherapy sensitizer |
| CN106822129A (en) * | 2017-03-08 | 2017-06-13 | 中国医学科学院医药生物技术研究所 | Application of the aloperine derivative in the medicine for preparing treatment tumour |
| CN106822129B (en) * | 2017-03-08 | 2019-09-03 | 中国医学科学院医药生物技术研究所 | Application of the aloperine derivative in the drug of preparation treatment tumour |
| CN108840871A (en) * | 2018-07-18 | 2018-11-20 | 陕西科技大学 | 13- hydroxyl sparteine cinnamate derivative compound with anti-tumor activity and preparation method thereof |
| CN108840871B (en) * | 2018-07-18 | 2021-12-17 | 西安泰科迈医药科技股份有限公司 | 13-hydroxy cytisine cinnamate compound with anti-tumor activity and preparation method thereof |
| CN109055313A (en) * | 2018-08-29 | 2018-12-21 | 青海七彩花生物科技有限公司 | A kind of application of alkaloid in enhancing CIK cell proliferative capacity and in terms of killing tumor activity |
| CN109055313B (en) * | 2018-08-29 | 2021-11-02 | 山东兴瑞生物科技有限公司 | Application of alkaloid in enhancing CIK cell proliferation capacity and antitumor activity |
| CN109172570A (en) * | 2018-09-13 | 2019-01-11 | 淮安亿泰生物科技有限公司 | A kind of application of alkaloid in the drug of preparation prevention and treatment patients with lung cancer cisplatin-resistant |
| CN109200050A (en) * | 2018-09-13 | 2019-01-15 | 淮安亿泰生物科技有限公司 | Application of the alkaloid in terms of reversing lung cancer cisplatin-resistant |
| CN109172569A (en) * | 2018-09-13 | 2019-01-11 | 淮安亿泰生物科技有限公司 | A kind of alkaloid compound for preventing and treating patients with lung cancer cisplatin-resistant |
| CN109200050B (en) * | 2018-09-13 | 2020-11-20 | 普瑞赛森(山东)生物医学科技有限公司 | Application of alkaloid in reversing drug resistance of lung cancer cisplatin |
| CN109172569B (en) * | 2018-09-13 | 2020-12-22 | 浙江亚瑟医药有限公司 | Alkaloid compound for preventing and treating cisplatin resistance of lung cancer patient |
| CN109172571B (en) * | 2018-09-13 | 2021-03-02 | 泉州智慧果技术服务有限公司 | Application of alkaloid in reversing drug resistance of cisplatin in lung cancer |
| CN109172571A (en) * | 2018-09-13 | 2019-01-11 | 淮安亿泰生物科技有限公司 | A kind of alkaloid is used to reverse the purposes of lung cancer cisplatin-resistant |
| CN109045031A (en) * | 2018-09-13 | 2018-12-21 | 淮安亿泰生物科技有限公司 | A kind of alkaloid reversing lung cancer cisplatin-resistant |
| CN114573585A (en) * | 2020-12-01 | 2022-06-03 | 中国医学科学院药物研究所 | Alkaloid extracted from herba Sophorae Alopecuroidis, its pharmaceutical composition, and its application in preventing and treating tumor |
| CN114573585B (en) * | 2020-12-01 | 2023-12-15 | 中国医学科学院药物研究所 | Alkaloid extracted from herba Sophorae Alopecuroidis, pharmaceutical composition thereof and application thereof in preventing and treating tumor |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102008475B (en) | 2012-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102008475B (en) | Application of quinolizidine in preparing tumor treatment drugs | |
| CN105769891B (en) | Low polarity rare ginsenoside mixture and application thereof | |
| CN113262258B (en) | Flos Potentillae Anserinae extract, its medicine, and its preparation method and application | |
| CN103768534A (en) | Traditional Chinese medicinal composition with anti-tumor activity | |
| CN101502579B (en) | Chinese medicinal composition for treating digestive tumor and preparation method thereof | |
| WO2009109109A1 (en) | Use of tea polyphenols in preparing medicaments for prevention or treatment of tumors | |
| CN101152165A (en) | Antineoplastic isoliquirtigenin tablet | |
| CN102133220B (en) | Preparation method of pulsatilla saponin A | |
| CN102908340B (en) | Isolicoflavonol-containing antitumor drug and application thereof | |
| CN103893188A (en) | Application of ilexgenin A in preparation of anti-tumor medicaments | |
| CN103893412B (en) | A kind of antitumor beautyberry extract and its production and use | |
| CN103655559B (en) | Horned artemisia ester alkali compounds is preparing the application in anti-breast cancer medicines | |
| CN105380968A (en) | Nitraria-tangutorum-bobr total alkaloid extract, preparing method thereof and application thereof | |
| CN101245089A (en) | Process for producing a pair of novel ginsengenin and its compound body, and preparations thereof | |
| CN101085804A (en) | Method for preparing lonicera macranthoides hypo-saponin B and application of the same in curing liver cancer, breast carcinoma and cervical cancer | |
| CN101982171B (en) | Application of fenugreek biflavone glycosides for preparing anti-virus or/and anti-tumor drugs | |
| CN114712377A (en) | Application of clinopodium polycephalum saponin A in preparing medicine | |
| CN1939311B (en) | Ginseng sapogenin aglycone derivative biological preparation and its usage | |
| CN102988525A (en) | Preparation method for total lignans in hawthorn seeds, and novel application | |
| CN103211898B (en) | Traditional Chinese medicine extractive and preparation method thereof | |
| CN102858359A (en) | Medicinal composition comprising alcohol-soluble and water-insoluble licorice extract, pharmaceutical preparation, pharmaceutical application, therapeutic method, and preparative method thereof | |
| CN102702215B (en) | Compound mangostenone F, preparation method and application in preparation of antitumor drugs thereof | |
| CN101805384B (en) | Novel lycoris quinolone alkaloid and preparation method and application thereof | |
| CN110585287A (en) | Application of Nauclea officinalis extract in preparation of antitumor drugs | |
| CN103919819A (en) | Poria cocos natural composition and anti-cancer vomit-preventing application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121219 Termination date: 20130909 |